AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...

AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve ...

The F.D.A. authorized AstraZeneca’s treatment to be given outside a health care setting, although it will still need a ...

A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer ...

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” second quarter 2024 ...

AstraZeneca PLC AZN shares dropped 1.66% to £115.84 Monday, on what proved to be an all-around great trading session for the ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically ...

The approved indication involves using durvalumab in combination with chemotherapy as a neoadjuvant treatment, followed by ...

A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ...

UK shares ended higher on Monday, driven by gains in commodity-linked shares, particularly precious metal miners, amidst rising gold prices. Heavyweight energy shares also tracked elevated crude oil ...

It said the drug did not 'achieve statistical significance' in terms of the survival rates of those suffering from breast ...